Follistatin-344 — a peptide studied for its potential to increase muscle mass by blocking myostatin.
Follistatin-344 (FS-344) is one of two main circulating forms of follistatin, a natural protein the body uses to regulate muscle growth. It works primarily by binding and neutralizing myostatin — the signaling molecule that tells skeletal muscle to stop growing. Remove that brake, and muscle tissue has room to expand beyond its usual genetic ceiling.
Interest in FS-344 grew out of decades of research showing that animals with disabled myostatin develop dramatically larger muscles without obvious harm. Follistatin offered a way to mimic that effect pharmacologically rather than genetically. The 344 designation refers to the 344-amino-acid isoform, which has different tissue-binding properties than the shorter FS-315 form and is the variant most commonly produced for research.
The peptide has attracted attention in sports medicine and bodybuilding circles for its muscle-building potential, but it occupies an unusual position in the research landscape — strong mechanistic data, compelling results in large-animal studies, and a notable lack of formal human trials. It sits on the World Anti-Doping Agency's prohibited list as a myostatin inhibitor.
2 vendors carry Follistatin-344.
Compare prices →The clearest evidence for follistatin-344's muscle-building potential comes from a transgenic pig study in which animals were engineered to overexpress human FS-344 specifically in muscle tissue (3). The treated pigs showed a significantly higher lean meat percentage — about 73% compared to 69% in controls — along with reduced body fat and visible enlargement of individual muscle fibers in the back muscles. Importantly, no heart enlargement or reproductive issues were observed, suggesting the muscle-building effect was relatively contained to skeletal muscle when expression was tissue-specific.
The mechanism behind these changes involves two parallel signaling shifts. FS-344 reduced phosphorylation of Smad2, a protein that normally carries the myostatin growth-inhibition signal into muscle cells (3). At the same time, it increased phosphorylation of Akt, a key activator of the muscle protein synthesis pathway. In effect, the peptide simultaneously released the brake on muscle growth and pressed the accelerator — a combination that may explain why follistatin produces larger effects than simply knocking out myostatin alone.
A 2026 review of peptides used in sports medicine notes that follistatin-344 has shown favorable muscle and tissue outcomes in laboratory work but emphasizes that rigorous human safety data remain scarce (4).
One of the most important pieces of human-relevant data on FS-344 comes from an unexpected direction. A 2020 case series documented 11 male bodybuilders who developed central serous chorioretinopathy (CSCR) — a condition where fluid accumulates under the retina, causing blurred or distorted vision — after self-injecting high doses of follistatin-344 (1). All had injected complete 1 mg vials subcutaneously to increase muscle mass.
In the eight patients who had taken only a single high-dose injection, the subretinal fluid resolved on its own within roughly 2.3 months and vision returned. However, three patients who had injected multiple times went on to develop recurrent CSCR. The authors concluded that follistatin-344 injection should be considered a potential risk factor for CSCR and recommended that clinicians ask about follistatin use when investigating unexplained cases.
This is a meaningful signal because CSCR is associated with elevated cortisol-related signaling, and follistatin's effects extend beyond myostatin to include activin and other TGF-β family members involved in stress and steroid pathways. It illustrates that the peptide's biological reach is broader than simple muscle regulation.
A 2019 anti-doping investigation tested 17 follistatin products purchased through underground channels and produced a striking finding: only nine actually contained follistatin (2). The remaining products contained entirely different compounds, including mechano growth factor (MGF) and the growth hormone-releasing peptide GHRP-2 — substances with very different effects and risk profiles than what was on the label.
Even the products that did contain follistatin had a notable feature: all were His-tagged FS-344, a laboratory-modified version with a small histidine sequence attached for purification purposes, and most contained significant amounts of protein oligomers (clumped multi-unit forms) rather than clean monomeric peptide. The His-tag is a research tool, not a feature of any approved pharmaceutical, and it makes exogenous FS-344 chemically distinguishable from the body's own follistatin — which is exactly what allowed researchers to develop a urine and serum detection method for anti-doping use.
The practical implication is that products sold as follistatin-344 vary enormously in identity, purity, and form, which complicates any attempt to interpret user-reported outcomes.
The most significant reported adverse effect is central serous chorioretinopathy, a treatable but potentially recurrent retinal condition documented in 11 high-dose users (1). Single-injection cases resolved within roughly 2.3 months; repeat users showed recurrence. Anyone considering FS-344 should be aware that vision changes warrant immediate evaluation.
Product quality is a separate concern: testing of black market follistatin found that nearly half of products contained no follistatin at all, and those that did contained His-tagged research-grade material with significant oligomer content (2).
The body of follistatin-344 evidence comes primarily from preclinical and laboratory work, with limited human clinical data so far.
Follistatin is on the World Anti-Doping Agency's prohibited list as a myostatin inhibitor — relevant context for competitive athletes.
All information on this site is for research and educational purposes only. The compounds discussed are not approved by the FDA and are not intended to diagnose, treat, cure, or prevent any disease.